Cover Image

Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial

Proton-pump inhibitors (PPI) are liberally prescribed in patients with liver cirrhosis. Observational studies link PPI therapy in cirrhotic patients with an increased risk for infectious complications, hepatic encephalopathy and an increased risk for hospitalization and mortality. However, patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Wehmeyer, Malte Hermann (Author) , Horvatits, Thomas (Author) , Buchholz, Anika (Author) , Krause, Linda (Author) , Walter, Sarah (Author) , Zapf, Antonia (Author) , Lohse, Ansgar W. (Author) , Kluwe, Johannes (Author)
Format: Article (Journal)
Language:English
Published: 12 April 2022
In: Trials
Year: 2022, Volume: 23, Pages: 1-13
ISSN:1468-6694
DOI:10.1186/s13063-022-06232-w
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s13063-022-06232-w
Get full text
Author Notes:Malte H. Wehmeyer, Thomas Horvatits, Anika Buchholz, Linda Krause, Sarah Walter, Antonia Zapf, Ansgar W. Lohse, Johannes Kluwe and the STOPPIT-trial group
Description
Summary:Proton-pump inhibitors (PPI) are liberally prescribed in patients with liver cirrhosis. Observational studies link PPI therapy in cirrhotic patients with an increased risk for infectious complications, hepatic encephalopathy and an increased risk for hospitalization and mortality. However, patients with liver cirrhosis are also considered to be at risk for peptic ulcer bleeding. The STOPPIT trial evaluates if discontinuation of a pre-existing PPI treatment delays a composite endpoint of re-hospitalization and/or death in patients (recently) hospitalized with liver cirrhosis compared to patients on continued PPI medication.
Item Description:Gesehen am 11.05.2022
Physical Description:Online Resource
ISSN:1468-6694
DOI:10.1186/s13063-022-06232-w

Similar Items